Patent intelligence · US
US 9289513
Targeted cytokine for treatment of musculoskeletal diseases
Targeted cytokine for treatment of musculoskeletal diseases
Patent details — US 9289513
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 22, 2016
- Expiration
- Mar 17, 2036
- Applicant
- OPTION PHARMACEUTICALS, LLC
- Claims
- 8
- CPC classes
- A61K, A61K38/1841, A61K47/6811
Quick answer
US 9289513 (Targeted cytokine for treatment of musculoskeletal diseases) is held by OPTION PHARMACEUTICALS, LLC. Status: granted. Granted Mar 22, 2016. Expires Mar 17, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- OPTION PHARMACEUTICALS, LLC
- Grant date
- Expiration
- Claims
- 8
- CPC classes
- A61K, A61K38/1841, A61K47/6811
More from OPTION PHARMACEUTICALS, LLC
Related pharmaceutical patents in our USPTO index.
-
US 11596610
Compositions in support of health and mental accuity
granted -
US 10117937
Highly branched alpha-D-glucans
granted -
US 8685932
Targeted transforming growth factor-beta-bound IgG for Treatment of Diseases
granted -
US 6770283
DNA expression systems based on alphaviruses
expired -
US 6692750
Alphavirus expression vector
expired -
US 6566093
Alphavirus cDNA vectors
expired -
US 6224879
Alphavirus expression vector
expired
Frequently asked questions
What is US patent 9289513?
US 9289513 (Targeted cytokine for treatment of musculoskeletal diseases) is held by OPTION PHARMACEUTICALS, LLC. Status: granted. Granted Mar 22, 2016. Expires Mar 17, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9289513?
OPTION PHARMACEUTICALS, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 10 pharmaceutical patents for this assignee.
When does US 9289513 expire?
Our index shows an expiration date of Mar 17, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.